1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points:
Record sales orders close to $35 million and 32% growth in shipment revenue for Compumedics (ASX:CMP)Expansion in SaaS home sleep services and soon-to-launch disposable Somfit device targeting new marketsCommercialisation of MEG brain imaging systems delivers significant revenue in early yearsStrategic relationships with ResMed (ASX:RMD), Philips, and a dominant share in Australian pharmacy chains for sleep solutionsPositive outlook for US market growth, supported by increased investment in sales and marketing
Compumedics (ASX:CMP) has reported record sales orders nearing $35 million for the half year, with executive chairman Dr David Burton highlighting a 32% increase in shipped revenue for the December period. Burton states the company’s momentum remains strong, driven by renewed focus on commercial execution and a robust pipeline in both its core and emerging product divisions. Attention is now on delivering an even stronger second half, underpinned by continued order growth and delivery performance.
Burton outlines Compumedics’ global leadership in sleep and neurodiagnostic equipment, noting ongoing expansion into web-based SaaS home sleep services through its Somfit device. The upcoming launch of a disposable Somfit product, aimed at capitalising on the large disposable sleep-testing market, is flagged as a major growth catalyst. Additionally, the commercialisation of the company’s MEG brain imaging systems has resulted in approximately $25 million in revenue in the initial years, signalling further potential in this domain.
Major industry players such as ResMed (ASX:RMD) and Philips are noted as key customers, with Compumedics securing roughly 75% of the Australian pharmacy chain market for sleep services. Burton expresses confidence in further expansion, particularly in the US, with new investments and management strengthening the sales and marketing front. The company’s funding and balance sheet are described as solid, aided by the commercial returns from substantial R&D investments.
